Haemonetics is showing early signs of a turnaround, with Q1 FY2027 revenue up 5.6% YoY and gross margin expanding to 59.8%, the highest in recent quarters. However, the company's elevated leverage (D/E of 1.40) and persistent TTM revenue decline of 2.0% warran...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | $1.14+5.6% vs $1.08 | $339M+3.5% vs $328M |
Q2 2026 May 7, 2026 | $1.29+0.8% vs $1.28 | $346M+2.8% vs $337M |
Q1 2026 Feb 5, 2026 | $1.31+3.1% vs $1.27 | $339M+2.1% vs $332M |
Q4 2025 Nov 6, 2025 | $1.27+13.4% vs $1.12 | $327M-0.7% vs $330M |
Intellia Therapeutics NASDAQ: NTLA executives outlined plans for a potential launch of its hereditary angioedema treatment, lonvo-z, while discussing the company's ongoing Phase III program in transthyretin amyloidosis and its capital position during a Morgan Stanley event.
Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Haemonetics (HAE). But which of these two stocks presents investors with the better value opportunity right now?
Payment follows approximately $5 million received in January 2026, bringing total cash proceeds received to approximately $11 million Company remains eligible for up to approximately $10 million in additional proceeds through future revenue earnouts Monetization of a strategic holding provides additional capital to advance Orchestra BioMed's pivotal programs and reflects its approach to creating value through partnerships NEW HOPE, Pa., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced the receipt of $6.1 million on September 14, 2026, as the first milestone payment in connection with the previously announced acquisition of Vivasure Medical Limited (“Vivasure”) by Haemonetics Corporation (NYSE: HAE, “Haemonetics”).
NTLA's BLA for lonvo-z wins FDA priority review for the treatment of HAE. A decision from the agency is expected by March 10, 2027.
Benchmark HAE against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Haemonetics Corporation (HAE)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $106.82 | $4.85B | 52.11 | -1.97% | 7.29% | 12.03% | — | |
| $121.75 | $5.39B | -6.01 | -34.61% | -39.58% | -31.83% | — | |
| $76.01 | $16.97B | 30.53 | 1.74% | 13.18% | 11.01% | — | |
| $126.32 | $4.29B | 43.71 | 7.57% | 6.97% | 7.43% | — | |
| $16.25 | $1.88B | -13.32 | 8.28% | -21.25% | -44% | — | |
| $0.70 | $48.57M | -0.60 | 15.4% | -747.19% | -94.35% | — |
Haemonetics Corporation (HAE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Haemonetics Corporation (HAE) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jul 28, 2026·SEC
Jun 5, 2026·SEC
Get notified when HAE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Haemonetics Corporation (HAE) stock FAQ — growth, dividends, profitability & financials explained
Haemonetics Corporation (HAE) reported $1.35B in revenue for fiscal year 2026. This represents a 336% increase from $309.8M in 1997.
Haemonetics Corporation (HAE) saw revenue decline by 2.0% over the past year.
Yes, Haemonetics Corporation (HAE) is profitable, generating $96.3M in net income for fiscal year 2026 (7.3% net margin).
Haemonetics Corporation (HAE) has a return on equity (ROE) of 12.0%. This is reasonable for most industries.
Haemonetics Corporation (HAE) generated $291.2M in free cash flow for fiscal year 2026. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
